Sanofi SA
PAR:SAN

Watchlist Manager
Sanofi SA Logo
Sanofi SA
PAR:SAN
Watchlist
Price: 93.17 EUR 2.53% Market Closed
Market Cap: 116.8B EUR
Have any thoughts about
Sanofi SA?
Write Note

Intrinsic Value

The intrinsic value of one SAN stock under the Base Case scenario is 109.65 EUR. Compared to the current market price of 93.17 EUR, Sanofi SA is Undervalued by 15%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SAN Intrinsic Value
109.65 EUR
Undervaluation 15%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Sanofi SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for SAN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about SAN?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Sanofi SA

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Sanofi SA

Provide an overview of the primary business activities
of Sanofi SA.

What unique competitive advantages
does Sanofi SA hold over its rivals?

What risks and challenges
does Sanofi SA face in the near future?

Has there been any significant insider trading activity
in Sanofi SA recently?

Summarize the latest earnings call
of Sanofi SA.

What significant events have occurred
in Sanofi SA over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Sanofi SA.

Provide P/S
for Sanofi SA.

Provide P/E
for Sanofi SA.

Provide P/OCF
for Sanofi SA.

Provide P/FCFE
for Sanofi SA.

Provide P/B
for Sanofi SA.

Provide EV/S
for Sanofi SA.

Provide EV/GP
for Sanofi SA.

Provide EV/EBITDA
for Sanofi SA.

Provide EV/EBIT
for Sanofi SA.

Provide EV/OCF
for Sanofi SA.

Provide EV/FCFF
for Sanofi SA.

Provide EV/IC
for Sanofi SA.

Show me price targets
for Sanofi SA made by professional analysts.

What are the Revenue projections
for Sanofi SA?

How accurate were the past Revenue estimates
for Sanofi SA?

What are the Net Income projections
for Sanofi SA?

How accurate were the past Net Income estimates
for Sanofi SA?

What are the EPS projections
for Sanofi SA?

How accurate were the past EPS estimates
for Sanofi SA?

What are the EBIT projections
for Sanofi SA?

How accurate were the past EBIT estimates
for Sanofi SA?

Compare the revenue forecasts
for Sanofi SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Sanofi SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Sanofi SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Sanofi SA compared to its peers.

Compare the P/E ratios
of Sanofi SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Sanofi SA with its peers.

Analyze the financial leverage
of Sanofi SA compared to its main competitors.

Show all profitability ratios
for Sanofi SA.

Provide ROE
for Sanofi SA.

Provide ROA
for Sanofi SA.

Provide ROIC
for Sanofi SA.

Provide ROCE
for Sanofi SA.

Provide Gross Margin
for Sanofi SA.

Provide Operating Margin
for Sanofi SA.

Provide Net Margin
for Sanofi SA.

Provide FCF Margin
for Sanofi SA.

Show all solvency ratios
for Sanofi SA.

Provide D/E Ratio
for Sanofi SA.

Provide D/A Ratio
for Sanofi SA.

Provide Interest Coverage Ratio
for Sanofi SA.

Provide Altman Z-Score Ratio
for Sanofi SA.

Provide Quick Ratio
for Sanofi SA.

Provide Current Ratio
for Sanofi SA.

Provide Cash Ratio
for Sanofi SA.

What is the historical Revenue growth
over the last 5 years for Sanofi SA?

What is the historical Net Income growth
over the last 5 years for Sanofi SA?

What is the current Free Cash Flow
of Sanofi SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Sanofi SA.

Business Breakdown

Sanofi SA is a global healthcare leader, committed to improving health outcomes through the innovation and manufacturing of a diverse range of pharmaceutical products and vaccines. With its roots established over 150 years ago, the company operates a vast network that spans across 100 countries, employing over 100,000 individuals dedicated to advancing medical science. Sanofi's portfolio includes treatments in key therapeutic areas such as diabetes, cardiovascular diseases, and immunology, alongside its robust vaccine division, Sanofi Pasteur. This blend of established products and innovative pipelines, including biopharmaceuticals and gene therapies, positions Sanofi uniquely to meet the ev...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Sanofi SA

Current Assets 30.1B
Cash & Short-Term Investments 6.8B
Receivables 8.8B
Other Current Assets 14.5B
Non-Current Assets 99.7B
Long-Term Investments 2.6B
PP&E 11.9B
Intangibles 76.7B
Other Non-Current Assets 8.4B
Current Liabilities 30B
Accounts Payable 7.4B
Short-Term Debt 215m
Other Current Liabilities 22.4B
Non-Current Liabilities 27B
Long-Term Debt 14.2B
Other Non-Current Liabilities 12.8B
Efficiency

Earnings Waterfall
Sanofi SA

Revenue
61.6B EUR
Cost of Revenue
-18.8B EUR
Gross Profit
42.7B EUR
Operating Expenses
-28.7B EUR
Operating Income
14B EUR
Other Expenses
-7B EUR
Net Income
7B EUR

Free Cash Flow Analysis
Sanofi SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q3 2024, Sanofi achieved a remarkable €13.4 billion in sales, marking a 16% increase year-over-year at constant exchange rates. The strong performance was driven by Dupixent, which reported nearly €3.5 billion in sales, and a robust 26% growth in its vaccines segment. The company raised its 2024 EPS guidance, projecting at least a low single-digit percentage growth, previously expected to be flat. Beyfortus sales are projected to reach around €1.5 billion in 2024, while ongoing investments in R&D are expected to increase by €700 million this year, demonstrating a commitment to innovation and growth.

What is Earnings Call?
Fundamental Scores

SAN Profitability Score
Profitability Due Diligence

Sanofi SA's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive Operating Income
Positive Net Income
57/100
Profitability
Score

Sanofi SA's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

SAN Solvency Score
Solvency Due Diligence

Sanofi SA's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Low D/E
Long-Term Solvency
Average Altman Z-Score
71/100
Solvency
Score

Sanofi SA's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SAN Price Targets Summary
Sanofi SA

Wall Street analysts forecast SAN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SAN is 114.77 EUR with a low forecast of 90.9 EUR and a high forecast of 132.3 EUR.

Lowest
Price Target
90.9 EUR
2% Downside
Average
Price Target
114.77 EUR
23% Upside
Highest
Price Target
132.3 EUR
42% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for SAN?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for SAN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SAN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

SAN News

Other Videos

Profile

Sanofi SA Logo
Sanofi SA

Country

France

Industry

Pharmaceuticals

Market Cap

116.6B EUR

Dividend Yield

4.04%

Description

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 95,442 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

Contact

ILE-DE-FRANCE
Paris
54 Rue la Boetie
+33153774000.0
www.sanofi.com

IPO

2002-07-01

Employees

95 442

Officers

CEO & Director
Mr. Paul Hudson
Executive VP & CFO
Mr. François-Xavier Roger
Executive VP & Head of Business Operations
Ms. Madeleine Roach
Principal Accounting Officer and Vice President of Corporate Accounting
Mr. Laurent Gilhodes
Chief Science Officer of Consumer Health Care
Dr. Josephine Fubara
Head of Investor Relations
Mr. Thomas Kudsk Larsen
Show More
Global Compliance Officer & VP
Mr. Dante Beccaria
Executive VP & General Counsel
Mr. Roy Papatheodorou
Head of Communications
Mr. Josep Catlla
Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing
Mr. Pierre Chancel
Show Less

See Also

Discover More
What is the Intrinsic Value of one SAN stock?

The intrinsic value of one SAN stock under the Base Case scenario is 109.65 EUR.

Is SAN stock undervalued or overvalued?

Compared to the current market price of 93.17 EUR, Sanofi SA is Undervalued by 15%.

Back to Top